## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.13 indicates fundamental undervaluation. Quality metrics strong (ROE 30%, ROA 14%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-6.0% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($95.30)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 4, Bearish: 2)

**1. Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)**
- Source: Yahoo Finance Singapore | 20251203T213000 | Neutral | Relevance: 100%
- Incyte Corporation announced equity inducement awards to Richard Hoffman, the Companyâ€™s new Executive Vice President and General Counsel, under Nasdaq Listing Rule 5635(c)(4). These awards, approved by the compensation committee, include stock options to purchase 43,301 shares, restricted stock units for 9,466 shares, and performance shares with a target of 23,665 shares. The grants, effective December 1, 2025, are an inducement for his employment, with vesting schedules tied to continued service and company performance.

**2. Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)**
- Source: Markets Financial Content | 20251203T213000 | Somewhat-Bullish | Relevance: 100%
- Incyte Corporation announced equity inducement awards granted to Richard Hoffman, its new Executive Vice President and General Counsel. These awards, approved by the compensation committee, are an inducement for his employment in accordance with Nasdaq Listing Rule 5635(c)(4) and include stock options, restricted stock units, and performance shares.

**3. INCY: Late-stage pipeline and global expansion drive strong post-Jakafi growth outlook**
- Source: TradingView | 20251202T200615 | Bullish | Relevance: 100%
- Incyte Corporation outlined a post-Jakafi growth strategy focusing on its robust late-stage pipeline across hematology, oncology, and immunology, presenting multiple billion-dollar opportunities. Key assets like 989 for MPNs, the global expansion of Opzelura, povorcitinib for HS/PN/vitiligo, and solid tumor programs are expected to drive growth. This strategy is supported by strong execution and business development efforts.

**4. INCY: Late-stage pipeline and global expansion drive strong post-Jakafi growth outlook**
- Source: TradingView | 20251202T190613 | Bullish | Relevance: 100%
- Incyte Corporation's management has outlined a robust post-Jakafi growth strategy, focusing on a late-stage pipeline in hematology, oncology, and immunology with multiple billion-dollar opportunities. Key assets include 989 for MPNs, the global expansion of Opzelura, povorcitinib for HS and PN, and various solid tumor programs. This strategy is underpinned by strong execution and business development efforts.

**5. Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding**
- Source: Business Wire | 20251202T142129 | Bullish | Relevance: 100%
- Incyte announced a partnership with supermodel Winnie Harlow for "The Power of Choice" campaign to raise awareness about vitiligo. Harlow, who has lived with vitiligo most of her life, shares her personal journey and encourages others to understand the condition and explore treatment options. The campaign aims to empower individuals with vitiligo to make choices that are right for them, supported by healthcare professionals.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Barclays | $115 | $101 | +14% |
| 2025-11-04 | Piper Sandler | $102 | $82 | +24% |
| 2025-11-03 | Guggenheim | $125 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Barclays | main | Overweight |
| 2025-11-04 | Piper Sandler | main | Overweight |
| 2025-11-03 | Guggenheim | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.05M) |
| Sells | 20 ($25.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.0% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $26M sold (20 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Forward P/E 13.3x attractive for 14% earnings growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (2 raises, avg +19%). Insider selling cluster ($25.8M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.7B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 7.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 13.3 |
| Current P/E | 15.1 |
| YoY Growth | 13.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 1.4% to -4.6% (-6.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.6pp (needs >4.0% for momentum thesis). Underperforming sector by 4.4pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.33x) but short-term weakness (below SMA20). MACD histogram bearish (-0.99), momentum weakening. RSI neutral at 52. OFD pattern: -SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.63% (CS: 11) | Weak |
| RSI_14 | 52.2 | Neutral |
| MACD Histogram | -0.99 | Bearish |
| vs SMA20 | 0.972x | Below |
| vs SMA50 | 1.072x | Above |
| vs SMA200 | 1.331x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $101.50
- **Stop Loss:** $95.30 (6.1% risk)
- **Target:** $113.90 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 153
- **Position Value:** $15,529.50
- **Portfolio %:** 15.53%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*